Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

378
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
378
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

398
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation, certification and registration of veterinary diagnostic test kits by the World Organisation for Animal Health Secretariat for Registration of Diagnostic Kits.

Revue scientifique et technique (International Office of Epizootics)·2021
Same author

VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays.

Toxicology in vitro : an international journal published in association with BIBRA·2019
Same author

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs.

CPT: pharmacometrics & systems pharmacology·2015
Same author

Zoonotic protozoa in the marine environment: a threat to aquatic mammals and public health.

Veterinary parasitology·2014
Same author

A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6.

Clinical pharmacology and therapeutics·2013
Same author

Maternal critical care in the United Kingdom: developing the service.

International journal of obstetric anesthesia·2012

Related Experiment Video

Updated: May 3, 2026

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

17.3K

Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies.

L Li1, I Gardner1, R Rose1

  • 1Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.

CPT: Pharmacometrics & Systems Pharmacology
|January 31, 2014
PubMed
Summary

Shedding of the human epidermal growth factor receptor 2 (HER2) target affects trastuzumab drug levels. A pharmacokinetic model shows soluble HER2 significantly decreases trastuzumab concentrations in plasma.

More Related Videos

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Experiment Videos

Last Updated: May 3, 2026

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

17.3K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Area of Science:

  • Pharmacometrics and Systems Pharmacology
  • Biochemistry
  • Oncology

Background:

  • Shedding of pharmacological targets into soluble forms is common.
  • Soluble targets can bind therapeutic proteins, impacting drug efficacy.
  • Human epidermal growth factor receptor 2 (HER2) is a key target in cancer therapy.

Purpose of the Study:

  • To model the pharmacokinetics of trastuzumab considering both membrane-bound and soluble HER2.
  • To investigate the impact of varying HER2 levels and binding kinetics on trastuzumab concentrations.
  • To correlate model predictions with observed clinical changes in trastuzumab half-life.

Main Methods:

  • Development of a minimal physiologically based pharmacokinetic model.
  • Simulation of trastuzumab binding to both soluble and membrane-bound HER2.
  • Parameterization using in vitro data for trastuzumab-HER2 interactions.
  • Investigation of sensitivity to HER2 levels, affinity differences, and binding kinetics.

Main Results:

  • The model predicts a sharp decrease in trough trastuzumab concentrations at soluble HER2 levels of 500–1,000 ng/ml.
  • This concentration range aligns with clinical observations of altered trastuzumab half-life.
  • Model simulations highlight the significant influence of soluble HER2 on drug pharmacokinetics.

Conclusions:

  • Soluble HER2 significantly impacts trastuzumab pharmacokinetics, particularly trough concentrations.
  • Physiologically based pharmacokinetic modeling provides insights into drug behavior in the presence of soluble targets.
  • Understanding these interactions is crucial for optimizing cancer therapy regimens.